Trail camera captures bizarre farting moment from unexpected nighttime visitor: 'There is actually a good reason for this activity'
Have you heard that taking a short walk after dinner can help with digestion? Apparently, this tradition is not exclusive to humans. Scientists caught a keystone species taking an evening walk to flatulate.
"The beaver breaking wind gave the team a good giggle in the office and has continued to do so ever since," Lauren Jasper, beaver officer at Cornwall Wildlife Trust, told BBC's Discover Wildlife.
The scientists' important work included setting up trail cameras to learn about the beaver population in the area. Beavers are a keystone species, which means that their contribution to the ecosystem is great enough to disrupt the food chain if removed.
Trail cameras are powerful tools to help experts gauge population, behaviors, and overall health. Especially when it comes to endangered and keystone species, this research can make a massive difference in the health of a larger ecosystem.
In England, beavers were hunted to extinction over 400 years ago. Many efforts across the country have been made to restore the biodiversity that beavers encourage. "When you bring beavers back, other wildlife follows," Cheryl Marriott, director of nature & people at Cornwall Wildlife Trust, told Discover Wildlife.
Since reintroducing just two beavers to a wooded acreage with a stream in Cornwall in 2017, they have built eight new dams. Along with the dams came new ponds, which are now home to double the number of brown trout, 11 species of bats, 10 new species of birds recorded for the first time ever, 17 species of dragonflies, three species of mammals recorded for the first time ever, three new streams and 1,790 new square meters (1,927 square feet) of water surface, according to the Cornwall Beaver Project.
Beavers are master architects of rich biodiversity, even if they are a little smelly. "There is actually a good reason for this activity," Jasper said of the farting.
"The beaver might have been scent marking — they produce an oily substance from a gland near their tail to mark territory," reported Melissa Hobson for Discover Wildlife.
Should the U.S. invest in building more wildlife overpasses?
Absolutely
Depends on how we do it
Depends on where we do it
Nope
Click your choice to see results and speak your mind.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
2 hours ago
- Bloomberg
Reeves to Announce £86 Billion for Science and Technology in Spending Review
Save Research into drug treatments and longer-lasting batteries will receive new funding as part of an £86 billion package for science and technology set to be announced in next week's spending review. Regions will be handed up to £500 million with local leaders given powers to decide how investment is targeted in their communities, the Department for Science, Innovation and Technology (DSIT) said.
Yahoo
2 hours ago
- Yahoo
What eating foods like dark chocolate and berries did to a study group of more than 120,000 people
A new study reveals what drinking tea and eating dark chocolate and berries did for a group of more than 120,000 people. Those foods, as well as fruits like grapes, apples, oranges, and beverages like red wine, all contain flavonoids, which are compounds found in many plant products. Flavonoids can 'help your body function more efficiently while protecting it against everyday toxins and stressors,' per Healthline. The study's authors said those who consumed a diverse range of foods containing flavonoids (such as berries, grapes and dark chocolate) 'could lower their risk of developing serious health conditions and have the potential to live longer,' in a news release. The study has been peer-reviewed. In the study, which was recently published in the journal Nature Food, researchers observed 124,805 participants between the ages of 40 and 70 from the UK Biobank, a large-scale database with biomedical information. The participants were tracked for roughly 10 years and their dietary information was collected using a questionnaire asking them about the frequency in which they ate approximately 200 types of food and 30 beverages. Dr. Benjamin Parmenter, a research fellow at Edith Cowan University in Australia, was the study's first author and co-lead. He said consuming roughly 500 mg of flavonoids a day or more was linked to a 16 per cent lower risk of 'all-cause mortality' (meaning death from any cause). It was also linked to a roughly 10 per cent lower risk of cardiovascular disease, type 2 diabetes, and respiratory disease. A study published in 2025 in peer-reviewed food science journal Foods said, as it pertains to human health, 'flavonoids are recognized for their ability to combat aging, mitigate inflammation, safeguard the nervous system, and promote overall well-being.' However, in another study published in 2022 in the Nutrition Journal, researchers 'observed an increased risk of prostate cancer by higher intake of total flavonoids.' In a study published in 2016 in the Journal of Nutritional Science, researchers called for further studies on flavonoids so their usefulness 'in the diet could be improved for better human health.' 'Over 30 different types of flavonoids are regularly consumed in the human diet. These are found in different types of everyday foods,' Parmenter told National Post over email. A few squares of dark chocolate could be roughly 25 mg of flavonoids. One apple is equal to roughly 100 mg of flavonoids, while one orange is roughly 60 mg. For tea drinkers, one cup of black tea is roughly 300 mg of flavonoids, while the same amount of green tea is roughly 150 mg. 'We observed that consuming a higher quantity and wider diversity of dietary flavonoids, when consumed together, may represent the optimal approach for improving long-term health, compared with increasing either flavonoid quantity or diversity alone,' Parmenter said. Those with the highest flavonoid diversity were more likely to be female, older, have a lower body mass index (BMI), be more physically active and have a higher education and were less likely to be current smokers, according to the study. 'We also know from lab data and clinical studies that different flavonoids work in different ways, some improve blood pressure, others help with cholesterol levels and decrease inflammation,' said study co-lead professor Aedín Cassidy, per the news release. Cassidy is from the Co-Centre for Sustainable Food Systems and Institute for Global Food Security at Queen's University Belfast. The findings of the study show how 'simple and achievable dietary dietary swaps' can 'potentially improve health in the long-term,' she said. 'Dietary swaps, such as drinking more tea and eating more berries and apples for example, can help increase the variety and intake of flavonoid-rich foods, and potentially improve health in the long-term,' said Cassidy. According to researchers, no previous works appear to have reported on the human health benefits of a flavonoid-diverse diet. 'Consequently, replication of our findings in other cohorts and clinical trials will be critical, as will the exploration of flavonoid diversity with other disease outcomes. Interpretation, however, requires careful consideration,' said researchers, in the study. The study was led by researchers from Queen's University Belfast, Edith Cowan University Perth, and the Medical University of Vienna and Universitat Wien. Smoking one cigarette equals 20 minute off your life, study finds What drinking 3 cups of coffee daily did to a study group of more than 170,000 people Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here.
Yahoo
3 hours ago
- Yahoo
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner's Substack. In this article, we will summarize the bulls' thesis on CHRS. Coherus BioSciences, Inc. (CHRS)'s share was trading at $0.77 as of 30th May. CHRS's trailing P/E was 1.77 according to Yahoo Finance. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. Coherus BioSciences (CHRS), long overlooked by Wall Street, is taking a bold step into innovative oncology by partnering with UK-based STORM Therapeutics to test a novel cancer treatment strategy. The collaboration brings together Coherus's immunotherapy toripalimab (LOQTORZI) and STORM's first-in-class RNA-modifying enzyme inhibitor STC-15 in a Phase 1b/2 clinical trial. This unexpected pairing represents a fresh approach to immuno-oncology, targeting cancer through dual mechanisms that could produce synergistic effects. Toripalimab, already approved in the U.S. for nasopharyngeal carcinoma and under review for broader indications, offers proven checkpoint inhibition, while STC-15 introduces a cutting-edge method of disrupting RNA methylation processes linked to tumor growth and immune evasion. If this combo demonstrates efficacy, it could represent a completely new class of cancer therapy and place Coherus at the forefront of next-generation immuno-oncology innovation. Importantly, this partnership shows strategic vision from CHRS's management as they seek to differentiate the company beyond biosimilars and move deeper into proprietary immunotherapy. With the trial still in early stages and little market attention so far, the risk/reward profile for investors is potentially skewed to the upside. Should the data prove positive, the impact could be significant for both companies, especially for CHRS as it repositions itself as a serious player in oncology innovation. This under-the-radar development deserves close monitoring, as it could catalyze a major reevaluation of Coherus's valuation and growth trajectory. Previously, we have covered CHRS in March 2025 wherein we summarized a by the same author. Coherus BioSciences (CHRS) posted a strong turnaround in 2024 with $267M in revenue and $28.5M net income, driven by Loqtorzi's growth and the planned $250M Udenyca divestiture. The company pivoted fully to oncology, trimmed costs, and advanced its pipeline, yet management expressed frustration over the stock's undervaluation, hinting at potential M&A. Since our last coverage, the stock is down 38% as of 30th May. We don't trust CHRS' management as the stock lost more than 95% of its value in recent years and is still losing a ton of money. The market agrees with us and thinks this stock is going to go bankrupt. We believe CHRS should stop wasting shareholder's money, sell valuable assets, and liquidate the company. We don't think that's a likely outcome. Coherus BioSciences, Inc. (CHRS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held CHRS at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of CHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
